Nimulid efficacy and tolerability in patients with rheumatic diseases
https://doi.org/10.14412/1995-4484-2004-1383
Abstract
Objective. To study efficacy and safety of nimulid. Material and Methods. 33 pts with different rheumatic and vascular diseases were included in an open clinical trial of nimulid. Nimulid was administered 100-200 mg/day during 30 days. Disease modifying therapy was remained unchanged. Clinical and laboratory parameters were assessed before the start and after the end of therapy. Results. Significant improvement of all joint symptoms was achieved. 22(66,6%) pts showed good and 11(33,3%) - fair effect. Adverse events revealed in 5(7%) pts were mild and did not lead to the drug withdrawal. All adverse events were completely reversible. Conclusion. Our data show high efficacy and good tolerability of nimulid in this pts category.
References
1. <div><p>Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for asprin-like drugs. Nature, 1971,231,232-235</p><p>Mitchell J.A., Warner T.D. Cyclo-oxygenase-2:pharmacol- ogy, physiology, biochemistry and relevance to NSA1D 1132 therapy.Br.J.Pharmacol.,1999,128,1121-1132</p><p>Tavares I.A., Bishai P.M., Bennett A. Activity of nimesulide on constitutive and inducible cyclo-oxvgenases. Arzneim.- Forch /Drug Res., 1995,45,1093-1096 '</p><p>Warner T.D.,Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclooxy- genase-l rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA. 1999, 96, 7563-7568</p><p>Warner T.D. Introduction to "Nimesulide: Beyond COX- 2".Clin. Exp. rheumatol., 2001, 19(1), S1-S2.</p><p>Nimesulide: A multifactorial therapeutic approach to the inflammatory process? A 7-year clinical experience. Drugs. 1993, 46 (SI)</p><p>Magni E. Nimesulide an overview. Drug Ivest., 1991, 3, suppl. 2, 1-3</p><p>Ceserani R., Casciarri I.Cavallrtti E. et al. Action of nimesulide on rat gastric prostaglandins and renal function. Drug Invest., 1991,3, Suppl.2, 14-21.</p><p>Arnett F.C.,Edworth S.М., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthr.Rheum., 1988, 31, 315-324.</p></div><br />
Review
For citations:
Balabanova R.M., Grishaeva T.P., Siepaneis O.V. Nimulid efficacy and tolerability in patients with rheumatic diseases. Rheumatology Science and Practice. 2004;42(1):48-50. (In Russ.) https://doi.org/10.14412/1995-4484-2004-1383
Views:
784
Email this article 